Mustafa Kemal Universitesi

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials
• Obesity2 trials
• Crohn's disease1 trial

Phase

• Phase 22 trials
• Phase 32 trials

Status

• Recruiting4 trials

Lead sponsor

• Eli Lilly and Company4 trials

Running trials

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Mehmet Demir (principal investigator)

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Mehmet Demir (principal investigator)

• Recruiting

  Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  NCT06937099· Phase 3· Eli Lilly and Company· Source

  Contact: Mehmet Demir (principal investigator)

• Recruiting

  Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  NCT06937086· Phase 3· Eli Lilly and Company· Source

  Contact: Mehmet Demir (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis3 recruiting
• Obesity2 recruiting
• Crohn's disease1 recruiting